Aaron John Spittler

468 total citations
18 papers, 330 citations indexed

About

Aaron John Spittler is a scholar working on Oncology, Neurology and Surgery. According to data from OpenAlex, Aaron John Spittler has authored 18 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Neurology and 4 papers in Surgery. Recurrent topics in Aaron John Spittler's work include Cancer Treatment and Pharmacology (9 papers), Myasthenia Gravis and Thymoma (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Aaron John Spittler is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Myasthenia Gravis and Thymoma (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Aaron John Spittler collaborates with scholars based in United States. Aaron John Spittler's co-authors include Patrick J. Loehrer, Arun Rajan, Éva Szabó, Arlene Berman, Christina Brzezniak, Udayan Guha, Giuseppe Giaccone, Anish Thomas, Yisong Wang and Jane B. Trepel and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Aaron John Spittler

18 papers receiving 327 citations

Peers

Aaron John Spittler

NEURO

ONCOL

EDM

EPIDE

Jillian Thompson United States

Hendrik Blaeker Germany

Lily Yang United States

Meredith Davis United States

Rahel Sahli Switzerland

Colleen Veloski United States

Masako Kanbe Japan

Frank J. Quayle United States

Julia Wendler Germany

Ofra Maimon Israel

Jillian Thompson United States

Aaron John Spittler

226 ×1.0

NEURO

165 ×1.3

ONCOL

79 ×0.7

EDM

40 ×0.8

EPIDE

28 ×0.8

Citations per year, relative to Aaron John Spittler Aaron John Spittler (= 1×) peers Jillian Thompson

Countries citing papers authored by Aaron John Spittler

Since Specialization

Citations

This map shows the geographic impact of Aaron John Spittler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron John Spittler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron John Spittler more than expected).

Fields of papers citing papers by Aaron John Spittler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron John Spittler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron John Spittler. The network helps show where Aaron John Spittler may publish in the future.

Co-authorship network of co-authors of Aaron John Spittler

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron John Spittler. A scholar is included among the top collaborators of Aaron John Spittler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron John Spittler. Aaron John Spittler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Radovich, Milan, Sandra K. Althouse, Hao Liu, et al.. (2022). A phase II study of buparlisib in relapsed or refractory thymomas. Frontiers in Oncology. 12. 891383–891383. 10 indexed citations

Turk, Anita, Amikar Sehdev, Safi Shahda, et al.. (2020). A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology. 38(15_suppl). e16764–e16764. 5 indexed citations

Hellyer, Jessica A., Matthew A. Gubens, Kristen Cunanan, et al.. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 137. 71–75. 11 indexed citations

Radovich, Milan, Sandra K. Althouse, Hai Liu, et al.. (2018). A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.. Journal of Clinical Oncology. 36(15_suppl). e20580–e20580. 3 indexed citations

Kalra, Maitri, Gregory A. Coté, Rebecca S. Heist, et al.. (2018). A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma.. Journal of Clinical Oncology. 36(15_suppl). e20578–e20578. 5 indexed citations

Rajan, Arun, Chul Kim, Udayan Guha, et al.. (2017). OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma. Journal of Thoracic Oncology. 12(1). S313–S314. 6 indexed citations

Armstrong, Samantha, Paul R. Helft, Michael G. House, et al.. (2017). Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 17(2). e229–e232. 4 indexed citations

Hitron, Matthew, Aaron John Spittler, Gregory A. Coté, et al.. (2017). A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e20001–e20001. 1 indexed citations

Shahda, Safi, et al.. (2016). Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. The Oncologist. 21(6). 664–665d. 13 indexed citations

10.

Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies. Journal of Thoracic Disease. 7(3). 101. 1 indexed citations

11.

Khawaja, Muhammad Rizwan, et al.. (2015). Ocular metastasis of colorectal cancer. Hematology/Oncology and Stem Cell Therapy. 8(4). 176–180. 22 indexed citations

12.

Thomas, Anish, Arun Rajan, Arlene Berman, et al.. (2015). Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet Oncology. 16(2). 177–186. 197 indexed citations

13.

Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).. Journal of Clinical Oncology. 33(15_suppl). 7580–7580. 5 indexed citations

14.

Chiorean, E. Gabriela, Joel Picus, T. Breen, et al.. (2015). Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102.. Journal of Clinical Oncology. 33(15_suppl). 3618–3618. 4 indexed citations

15.

Chiorean, E. Gabriela, Bryan P. Schneider, Fatih Akisik, et al.. (2014). Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. 89(2). 284–291. 26 indexed citations

16.

Thomas, Anish, Arun Rajan, Arlene Berman, et al.. (2014). Phase II trial of sunitinib in patients with thymic epithelial tumors (TET).. Journal of Clinical Oncology. 32(15_suppl). 7525–7525. 10 indexed citations

17.

Shahda, Safi, Ming Yu, Joel Picus, et al.. (2011). Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102—Final report.. Journal of Clinical Oncology. 29(15_suppl). 3587–3587. 6 indexed citations

18.

Yu, Ming, Joel Picus, José A. Bufill, et al.. (2011). Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102.. Journal of Clinical Oncology. 29(4_suppl). 523–523. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact